Top 50 Ai For Genomics in Europe

This startup uses AI to analyze previously unexamined regions of the human genome, translating complex genetic data into actionable insights. Their technology helps healthcare providers enhance patient care and accelerates drug discovery by revealing new genetic associations.

The startup employs AI algorithms to analyze genetic data for identifying mutations associated with hereditary diseases. This technology enables healthcare providers to deliver accurate diagnoses and tailored treatment plans for patients with genetic disorders.

Aixa develops AI-driven biotech software that utilizes predictive genomics modeling to provide accessible health insights comparable to standard lab tests. By synthesizing advanced genomics data and medical literature, Aixa enables individuals to leverage personalized health solutions for improved healthspan.

SeqOne provides a clinical decision support platform that utilizes AI-driven bioinformatics to analyze next-generation sequencing (NGS) data for germline and somatic variants. The platform enhances diagnostic accuracy and efficiency by identifying complex genomic events that standard pipelines often overlook, thereby improving patient outcomes in precision medicine.

WhiteLab Genomics utilizes a proprietary platform that combines graph knowledge technology and machine learning to optimize the design of payloads and vectors for gene and cell therapies. This technology accelerates the development process, reducing costs and time to market for genomic medicines, making them more accessible to patients.

DNA-LM develops a universal language model pre-trained on diverse DNA sequences to process entire genomes. This model aims to accurately predict phenotypic traits across molecular and organism scales, reducing the need for extensive labeled data.

Curenetics utilizes an AI-powered platform that integrates genomics, imaging, and clinical data to predict individual patient responses to cancer therapies. This technology addresses the high variability in treatment effectiveness, enabling personalized treatment plans that improve patient outcomes and reduce unnecessary healthcare costs.

The startup operates a personal health and genomic data-sharing platform that connects users with researchers, enabling participation in studies on common and rare diseases. By allowing individuals to control their data and opt into research, the platform facilitates the collection of dynamic health and genetic datasets for personalized medicine.

Nygen Analytics offers a cloud-based platform for the analysis of single-cell genomic data, utilizing bioinformatics techniques to enable researchers to visualize and interpret complex datasets without requiring coding skills. The platform addresses the challenges of data complexity and collaboration in single-cell studies, facilitating efficient data management and accelerating research insights.

E9 Genomics develops computational genomics technologies that enable researchers to visually and instantaneously explore petabyte-scale genomic datasets. The platform addresses the challenge of limited access to diverse genetic insights, facilitating precision medicine and accelerating therapeutic research.

The startup offers a patient health data management platform that leverages artificial intelligence to aggregate and analyze diverse health data. By providing personalized longevity programs based on scientific breakthroughs, the platform enhances healthspan and delivers tailored health services to patients.

Genomate provides computational intelligence software to analyze a cancer patient's unique molecular profile and tumor alterations. This analysis predicts responses to multiple targeted therapies, enabling oncologists to select optimal, personalized treatment plans. The platform delivers data-backed reports to improve treatment outcomes and efficiency in precision oncology.

Ingenix provides a multimodal generative AI platform that builds digital twins of drug candidates by integrating genomics, proteomics, imaging, literature, and electronic health records across molecular to population scales. The system delivers detailed, interpretable predictions of clinical efficacy, safety endpoints, and adverse events, and supports natural‑language “what‑if” queries for trial design and candidate prioritization. It is aimed at pre‑clinical, strategic R&D, and clinical development teams in pharmaceutical and biotechnology companies.

The startup develops gene therapies using artificial intelligence to enhance the design and optimization of genetic constructs. Their technology enables researchers to create more predictable and controllable gene therapies, facilitating faster development for various applications.

gMendel utilizes advanced genomic sequencing and bioinformatics to enhance the diagnosis of genetic disorders, enabling precise identification of mutations. This technology improves disease management by providing clinicians with actionable insights for tailored treatment plans.

The startup provides a platform that facilitates access to AI-ready datasets specifically tailored for biomedical research. By streamlining data acquisition and integration, it enhances the efficiency of research workflows and accelerates the pace of scientific innovation.

TrueYouOmics utilizes DNA, RNA, and protein analyses, combined with AI-driven algorithms, to extract up to 3 billion datapoints from blood samples for personalized health risk assessments. The platform provides users with specific disease risk evaluations and tailored prevention plans, empowering them to make informed health decisions.

The startup operates a healthcare research and development platform that integrates real-world health and genomic data for observational studies and clinical trials. By providing insights into individual health and genetic ancestry, the platform enhances drug development and health care decision-making.

Panakeia delivers rapid, cost-effective multi-omics molecular analysis directly from routine H&E-stained tissue images using proprietary AI technology. This platform provides essential biomarker information in minutes, significantly accelerating the timeline compared to traditional physical testing methods. The resulting data enhances both clinical diagnostics and pharmaceutical drug development pipelines.

Artificial Intelligence Expert utilizes machine learning algorithms to analyze biomedical data, enhancing research accuracy and efficiency. The company addresses the challenge of data interpretation in the biomedical field, enabling researchers to derive actionable insights from complex datasets.

Enhanc3D Genomics utilizes its GenLink3D platform to analyze the 3D organization of DNA, focusing on the impact of genetic variations in non-coding regions on disease progression. This approach enables the identification of new biomarkers and treatment targets for complex conditions such as cancer, aging, and autoimmune diseases.

Helical AI provides a Virtual AI Lab platform that bridges the gap between machine learning models and biological decision-making in R&D. The platform offers biologists self-serve tools for designing and evaluating in-silico experiments, while ML engineers gain a production environment for model personalization and alignment. This integrated approach accelerates discovery in areas like target identification and therapeutic design, leading to higher hit rates for pharmaceutical research teams.

This company provides an AI copilot that analyzes diverse patient health data, including labs, genomics, and clinical notes, to identify overlooked diagnoses and future health risks. By unifying and harmonizing this complex data, the platform generates risk profiles benchmarked against medical guidelines and research. The system then recommends targeted AI follow-ups for doctors to confirm and implement proactive intervention strategies for patients.

Dyno Therapeutics utilizes artificial intelligence to design novel adeno-associated virus (AAV) vectors for gene therapy, enhancing delivery efficiency for a wide range of human diseases. The company aims to increase patient access to effective treatments while significantly reducing the cost of in vivo gene delivery.

This company utilizes genomics, machine learning, and bioengineering to access and cultivate previously unculturable microbial communities. They unlock novel chemistries evolved by these microbes for use in applications like antimicrobials and plant protectants. The focus is on developing effective, specific, and biodegradable solutions for healthcare and agriculture.

Lifebit CloudOS is a federated genomics platform that enables secure access and analysis of distributed clinical and multi-omic data without moving it from its original location. This technology addresses the challenge of fragmented health data, facilitating collaborative research and accelerating insights in precision medicine and drug discovery.

Multiomic Health develops precision medicines for diseases derived from metabolic syndrome by integrating multi-omics data with longitudinal clinical phenotyping. The company uses AI-enabled data science to identify distinct molecular disease drivers within patient subpopulations. This approach enables the origination of therapeutic R&D programs with corresponding patient-stratifying companion diagnostics for higher clinical trial success rates.

Ikerian offers a cloud‑native Discovery platform that ingests and standardizes multimodal patient data—including imaging, genomics and EHR records—and applies AI‑driven analytics to extract quantitative biomarkers and generate predictive disease‑outcome models. The system provides configurable dashboards, FHIR‑compatible APIs and automated workflow orchestration to support patient stratification, trial monitoring and evidence‑based decision making for pharma, CROs, hospitals and research institutions. Compliance‑first architecture ensures HIPAA, CE and FDA 510(k) compliance.

Heidelberg Epignostix develops precision cancer diagnostics through DNA methylation profiling and machine learning algorithms for accurate tumor classification. This technology enhances diagnostic accuracy, enabling healthcare providers to make informed decisions regarding cancer treatment and management.

Novigenix utilizes an AI-driven RNA sequencing platform to profile immune responses, enabling precise risk assessment and treatment predictions for cancer patients. The company addresses the challenge of heterogeneity in cancer treatment by providing actionable data for drug target discovery and early detection, particularly in colorectal cancer.

Wobble Genomics develops advanced computational tools for analyzing complex genomic datasets. The platform provides researchers with high-throughput sequence alignment and variant calling capabilities. This accelerates discovery in areas like personalized medicine and disease mechanism identification.

AIVIVO LTD develops artificial intelligence systems that generate multi-modal omics data to create OrganoMaps, which connect disease biology with treatment interventions at the organ level. This approach enables the development of targeted medicines for patients by providing insights into organ-specific disease mechanisms.

The startup develops clinically validated software applications that utilize artificial intelligence to analyze real-world data, enhancing patient outcomes and supporting the discovery of new medicines. By connecting patients, clinicians, and researchers, the platform generates extensive phenotypic databases that enable discovery research companies to maximize revenue in the healthcare sector.

The startup has developed a genome-analysis platform that facilitates the acquisition, analysis, and storage of genomic data without the need for repeated sequencing of the same genome for different tests. This technology enables healthcare providers to efficiently manage genetic data and deliver precise DNA sequencing services, enhancing the overall effectiveness of genomic research and patient care.

Vesalius Therapeutics employs a proprietary platform that utilizes patient-derived, cell-based experimental models and advanced data analytics to identify novel drug targets for complex diseases like heart failure and type II diabetes. By recognizing distinct clinical patterns linked to genetic variations, the company aims to develop targeted therapies that address the multifaceted nature of these prevalent illnesses.

Syndex Bio is a biotechnology platform that integrates molecular technologies and artificial intelligence to enhance the diagnosis and treatment of diseases. By providing advanced tools for biological discovery, the company aims to improve healthcare outcomes through more accurate and efficient disease management.

Watershed provides a platform for biological data analysis that integrates secure data management, customizable workflows, and supercomputing resources to enable rapid, large-scale analyses across various omics disciplines. By offering a dedicated bioinformatics team and ready-to-use AI tools, Watershed enhances productivity and collaboration for researchers facing the challenges of complex data interpretation.

Aneira applies computational biology and machine learning to provide health and care services for women and families. The company leverages advanced data analysis to offer personalized health insights and support.

This precision medicine company develops diagnostic and companion diagnostic (CDx) solutions by integrating multi-omics data with its proprietary explainable AI platform, ScaiVision. The platform analyzes complex biological data to identify predictive biomarkers, aiming to match patients with the most effective therapies, particularly in oncology and immune-mediated diseases. This approach translates deep biological insights into clinically validated assays that improve treatment efficacy and patient outcomes.

Quotient Therapeutics utilizes a Somatic Genomics platform to unlock the therapeutic potential of the vast genetic diversity within human cells, enabling the discovery of novel drug candidates. This approach addresses the limitations of traditional genomics by providing insights that lead to targeted treatments for a range of diseases.

Saphetor provides the VarSome Suite, a set of bioinformatics solutions that processes Next Generation Sequencing (NGS) data to generate clinically relevant genetic variation information. This technology enables healthcare professionals and researchers to access a comprehensive knowledge base and automated classification tools, enhancing the accuracy and efficiency of genomic analysis.

Akkure is a digital platform utilizing AI and genomics to enhance clinical trial recruitment for oncology by providing precise patient-trial matching and personalized trial recommendations. The platform ensures GDPR and HIPAA compliance, facilitating secure access and ownership of clinical data while streamlining the enrollment process for patients and healthcare providers.

The startup develops analytics software that integrates multi-omic data with AI analytics to enhance drug candidate identification and biomarker discovery. This technology enables precision medicine organizations to streamline research processes and significantly reduce time-to-market for new treatments.

Graph utilizes perturbation modeling from primary patient cell samples and multi-omics data to develop targeted therapies and biomarkers for immune-mediated diseases. The company addresses the lack of effective treatment options for millions of patients due to the complex nature of these diseases.

Ophiomics develops in vitro diagnostic devices that utilize artificial intelligence and genomics to enhance early cancer detection and optimize treatment selection. Their technology integrates machine learning algorithms with clinical and biomarker data to improve decision-making for clinicians, ultimately aiming to enhance patient outcomes in oncology.

Genenet Technology develops proprietary gene circuit designs by integrating deep learning algorithms to mimic artificial neural networks. This novel biocomputing method enables advanced control over gene expression for applications in synthetic biology and bioproduction. The company provides genetic circuit design services, R&D consultation, and technology licensing for drug discovery, cell and gene therapy, and organoid-on-chip research.

Ensocell is a biotechnology company developing next-generation precision biologics for autoimmune and fibrotic diseases. The company utilizes the ENSO AI platform to identify molecular targets and predict disease biology with high precision. This approach informs the design of tailored therapeutics with improved clinical success potential.

TwinEdge Bioscience provides a cloud‑based platform that creates high‑fidelity digital twins of individual patient tumors by integrating genomics, transcriptomics, proteomics and histopathology data. Its AI‑augmented simulation engine predicts drug response, resistance mechanisms and biomarker associations across a library of over 10,000 validated tumor avatars, enabling pharmaceutical and CRO teams to prioritize candidates, design trials and stratify patients before human enrollment.

Rayca Precision utilizes AI-driven bioinformatics platforms, OncoCrest™ and RSA2™, to analyze genomic and transcriptomic data for personalized cancer treatment strategies. The technology addresses the challenge of cancer heterogeneity by providing precise predictions of drug responses and patient outcomes, enabling tailored therapeutic interventions.

Healx provides an AI‑powered platform that integrates genomics, phenotypic and clinical data to identify and prioritize repurposed or optimized compounds for rare disease indications. The system automates in silico screening, predictive efficacy and safety modeling, and workflow orchestration to move candidates from computational prediction to preclinical validation, lowering discovery costs and timelines. It is offered to pharmaceutical, biotech and research consortium partners seeking to expand rare‑disease pipelines.